secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2023-10-05T23:59:59+00:00
Accession:  0001140361-23-047156
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01, 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Eterna receives Nasdaq delisting notice for audit committee non-compliance; director Fiore resigns
--------------------------------------------------------------------------------

- Nasdaq notified Eterna on Oct 3, 2023 that audit committee no longer meets minimum three-member/independence requirement after Binder and Wagner resignations.
- Cure period: until earlier of next annual meeting or Aug 9, 2024; if meeting before Feb 5, 2024, compliance due by Feb 5, 2024.
- Director Gregory Fiore resigned Oct 4, 2023; not due to any disagreement with the company.
- Nasdaq closed prior deficiency on independent director/audit/comp committee rules following appointment of Dorothy Clarke on Aug 31 and Sep 26, 2023.
- Company evaluating director candidates to regain compliance; listing continues under symbol ERNA on Nasdaq.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000114036123047156/0001140361-23-047156-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000114036123047156/ef20011972_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-047156

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer